Please assess the completion status of the following clinical trial:

Trial Title: A Clinical Trial of Retinal Gene Therapy for X-linked Retinitis Pigmentosa Using BIIB112

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 9.0

Eligibility Criteria:
Key Inclusion Criteria:~Part 1:~* Participants with genetically confirmed diagnosis of XLRP (with RPGR mutation).~* Participant with active disease clinically visible within the macular region in both eyes.~Part 2:~- Participant with mean total retinal sensitivity in the study eye as assessed by microperimetry ≥ 0.1 dB and ≤8 dB.~Key exclusion Criteria:~Parts 1 and 2:~* Participant with history of amblyopia in either eye.~* Participated in a gene therapy trial previously or a clinical trial with an investigational drug in the past 12 weeks or received a gene/cell-based therapy at any time previously.~NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.

- Gender: MALE
- Minimum Age: 10 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Part 1: BIIB112 Dose 1 (Type: EXPERIMENTAL): Participants will receive a single Dose 1 of BIIB112 by sub-retinal injection on Day 0.
- Part 1: BIIB112 Dose 2 (Type: EXPERIMENTAL): Participants will receive a single Dose 2 of BIIB112 by sub-retinal injection on Day 0.
- Part 1: BIIB112 Dose 3 (Type: EXPERIMENTAL): Participants will receive a single Dose 3 of BIIB112 by sub-retinal injection on Day 0.
- Part 1: BIIB112 Dose 4 (Type: EXPERIMENTAL): Participants will receive a single Dose 4 of BIIB112 by sub-retinal injection on Day 0.
- Part 1: BIIB112 Dose 5 (Type: EXPERIMENTAL): Participants will receive a single Dose 5 of BIIB112 by sub-retinal injection on Day 0.
- Part 1: BIIB112 Dose 6 (Type: EXPERIMENTAL): Participants will receive a single Dose 6 of BIIB112 by sub-retinal injection on Day 0.
- Part 2: BIIB112 High Dose (Type: EXPERIMENTAL): Participants will receive a single high dose of BIIB112 by sub-retinal injection.
- Part 2: BIIB112 Low Dose (Type: EXPERIMENTAL): Participants will receive a single low dose of BIIB112 by sub-retinal injection.
- Part 2: Untreated Group (Type: NO_INTERVENTION): Participants will receive no intervention to allow for a controlled comparison.

Based on this trial design, predict the completion outcome and termination type (if applicable).